Skip to content

Clinical trials

Recruiting Observational Multiple Sclerosis trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Multiple Sclerosis Phase: Observational Status: Recruiting Clear all

119 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20031
20081
20123
20131
20141
20163
20174
20181
20195
20203
20215
202210
202317
202423
202519
202620

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting119

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Heinrich-Heine University, Duesseldorf4
Novartis Pharmaceuticals4
University Hospital, Basel, Switzerland4
National Institute of Neurological Disorders and Stroke (NINDS)3
Washington University School of Medicine3
Afyonkarahisar Health Sciences University2
Assistance Publique - Hôpitaux de Paris2
Beijing Tiantan Hospital2
Bristol-Myers Squibb2
Central Hospital, Nancy, France2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Multiple Sclerosis119
Parkinson Disease13
Fatigue11
Neuromyelitis Optica11
Multiple Sclerosis, Relapsing-Remitting10
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease7
Alzheimer Disease6
Amyotrophic Lateral Sclerosis5
Autoimmune Diseases of the Nervous System5
Multiple Sclerosis, Chronic Progressive5

Trials

Showing 1 to 25 of 119. Each trial links to its page on Pharma Observatory.

19 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.